Together, We Can Bring Hope and Support to Families Impacted by Rare Diseases.
Patients
At Zogenix, patients and their families are central to everything we do. We strive to rapidly deliver treatments that address unmet medical needs, in order to change the lives of patients and their communities.
Investors
Zogenix, Inc. (NASDAQ: ZGNX) is committed to developing and commercializing transformative therapies for people living with rare diseases that can dramatically improve the lives of patients and their families.
Careers
We take pride in being a company who hires exceptional people who exemplify high standards and a passion to create significant value and benefits for healthcare professionals and their patients, our employees and our shareholders.
The Pipeline
We are advancing development of therapies for some of the most complex and severe forms of pediatric epilepsy, like Dravet syndrome and Lennox-Gastaut syndrome (LGS).
View All ProductsZX008 – Dravet syndrome
Lead investigational candidate, ZX008 (low-dose fenfluramine) for the treatment of Dravet syndrome
Formulation
Fenfluramine hydrochloride oral solution
Status
Phase 3 trials completed
ZX008 – Lennox-Gastaut syndrome
Investigational product candidate, ZX008 (low-dose fenfluramine) for the treatment of Lennox-Gastaut syndrome (LGS)
Formulation
Fenfluramine hydrochloride oral solution
Status
Global phase 3 trial ongoing
Our Story
Zogenix is committed to developing and commercializing transformative therapies to improve the lives of patients and their families living with rare diseases.